CSL partners on new coagulation treatment
| Stock | CSL Ltd (CSL.ASX) |
|---|---|
| Release Time | 16 Sep 2025, 8:01 a.m. |
| Price Sensitive | Yes |
CSL partners on new coagulation treatment
- CSL enters agreement with VarmX to develop new treatment to restore blood coagulation
- Treatment targets patients taking FXa inhibitors who experience severe bleeding or require urgent surgery
- CSL to fund VarmX's global Phase 3 trial and support late-stage development, manufacturing and commercialization
CSL Limited (ASX:CSL; USOTC:CSLLY) has announced that it has entered into an agreement with privately held Dutch biotech company, VarmX BV, to develop a new treatment to restore blood coagulation in patients taking a FXa inhibitor. More than 20 million patients globally take FXa inhibitors as chronic anticoagulation therapy, with approximately 3 per cent of these patients experiencing severe bleeding or requiring urgent surgery. VarmX's asset, VMX-C001, is a potentially first-in-class recombinant Factor X protein administered as a rapid single-dose, intended to bypass FXa anticoagulation activity and restore coagulation in patients experiencing severe bleeding or requiring urgent surgery. Under the terms of the collaboration agreement, CSL will fund VarmX's global Phase 3 trial evaluating VMX-C001 in patients taking Factor Xa inhibitors. CSL will also support late-stage product development, manufacturing and pre-launch commercial and medical affairs activities. CSL will make an upfront payment to VarmX of US$117 million for an exclusive option to acquire the company. CSL will have the right to exercise the option upon receipt of the Phase 3 data. Subject to the exercise of the option and certain milestones and regulatory clearances being reached, VarmX will receive payments of up to US$388 million up to the launch of VMX-C001, plus further commercial milestones thereafter. Commercial launch is anticipated in 2029.
The new treatment developed through the partnership between CSL and VarmX is expected to address a significant unmet medical need in a well-defined and growing patient population taking FXa inhibitors who experience severe bleeding or require urgent surgery. Commercial launch of the treatment is anticipated in 2029.